Target brain: neuroprotection and neurorestoration in ischemic stroke.
Many treatments for acute ischemic stroke are vessel and blood based, but brain-based therapies also hold great promise. Acute neuroprotective therapies block the molecular elaboration of injury in hypoxic environments. Prehospital trials of magnesium sulfate are demonstrating the feasibility of delivering potentially brain-protective agents in the first minutes after stroke onset. Subacute neurorestoration therapies enhance neuroplasticity and brain reorganization following stroke. The greatest clinical experience with agents that can potentiate brain repair has been gained with choline precursors. Therapies that target the brain in stroke patients will increasingly complement and enhance traditional vasotherapeutics.
Saver
Jeffrey L
JL
UCLA Stroke Center and Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D009473:Neuronal Plasticity / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D013997:Time Factors
D018696:Neuroprotective Agents